Teva Pharmaceutical Industries Ltd. topped out in 2015

Sep 7th, 2016 – 1 Comment

Dividend yield 2.67%


About the Author

Lou Schizas is an equities analyst, investor, entrepreneur, professor and television and radio personality – and a true believer in the happiness-inspiring powers of capitalism.


Read the author's full profile.


Further Research

Read more about Pharmaceuticals.


TEVA LOGO

Do you think investing in this stock is a good idea. Is now a good time to invest in it?

Sheila

 

 

Hey Sheila,

Thanks for the assignment. Teva Pharmaceutical Industries Ltd. (TEVA NYSE) is a global player in healthcare developing and producing generic and name brand drugs as well as active ingredients.

In the last number of weeks the company has lost patent protection on a compound that generates 20 % of revenue. But the decline in the stock started just over a year ago when it topped out near $70.00.

A probe of the charts will help identify if now would be a good time to buy.

 

 

TEVA

The three-year chart depicts a stock that has been dealing with an established downtrend line and resistance along the moving averages. The MACD and the RSI both generated sell signals in August of 2015 when the shares touched $70.00. The momentum indicators have provided buy and sell signals over the last year as TEVA traded in a down channel. At the moment there is no evidence to suggest that we can expect a trend reversal in the near term.

 

 

 

 

 

TEVA2

The six-month chart illustrates the trading opportunities the stock has offered since March. The best way to manage this investment is to look for profitable trades that might fit your risk tolerance. The dividend offers a yield of 2.67% but that doesn’t make TEVA a buy and hold stock.

 

Next time I’ll examine the charts for Dream Office Real Estate Investment Trust (D/UN TSX) for Kevin.

 

Make it a profitable day and happy capitalism!

Categories: Pharmaceuticals
Content © Relentless Economics - Charts courtesy Stockcharts.com - Employees Entrance - Optimization Media